Upper Respiratory Infections Linked to Nonadherence to Scheduled Chemotherapy
the Cancer Therapy Advisor take:
A patient’s adherence to their chemotherapy schedule is an integral aspect to an optimal treatment outcome. A prospective cohort study led by Ahmed Taha, MD, of the Sackler Faculty of Medicine, Tel-Aviv University in Tel-Aviv, Israel, looked into the factors that led to a dose reduction, a delay in chemotherapy, or a cancellation of a patient’s planned chemotherapy.
The focus of the research was mainly delays in chemotherapy because of a mild respiratory infection during the winter. The research included 547 adult patients with solid or hematologic cancer who were undergoing chemotherapy in a cancer center during the winter of 2010 to 2011. The researchers determined that 213 of the patients followed (38.9%) experienced 306 delays in chemotherapy treatment.
The documented reasons for the delays in chemotherapy were neutropenia (84/306, 27.4%), fever or infection (73/306, 23.9%), and thrombocytopenia (26/306, 8.5%). Upper respiratory infections (OR 1.87, 95% CI 1.27–2.76), prior hospitalization, lymphopenia, and peripheral vascular disease were all found to be independent risk factors for delayed chemotherapy treatment.
Researchers conducted an adjusted analysis that analyzed nonadherence to chemotherapy only because of an infection, that analysis determined that age alone and an upper respiratory infection (OR 5.25, 95% I 2.81–9.84) were significant independent risk factors. With this knowledge, the researchers encourage clinicians to assist their patients in preventing upper respiratory infections in order to avoid delays in chemotherapy schedules.
Factors examined for dose reduction, delay in chemotherapy, or cancellation of a planned chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer